Year: 2020

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) is pleased to provide an update on its commitment to social responsibility at its Kobada Gold Project in south-western Mali. With Mali experiencing one of the longest and wettest rainy seasons in recent memory, AGG’s team on the ground has been involved in assisting local stakeholders in keeping key roads and infrastructure open.The Samaya to Kobada road is a critical transport link from the Niger River that provides access for goods, services and medical facilities for several local communities. Due to the excessive rains this season, the road has become impassable in places. However, with the assistance of Etasi, the drilling contractor on site, and the wider AGG team, significant efforts have been made to keep the logistics...

Victor, NY, Nov. 09, 2020 (GLOBE NEWSWIRE) — Edoc Acquisition Corp. (NASDAQ: ADOCU) (the “Company”) announced today that it priced its initial public offering of 9,000,000 units at a price to the public of $10.00 per unit. The units are expected to commence trading on November 10, 2020 on the Nasdaq Capital Market under the symbol “ADOCU.”Each unit consists of one Class A ordinary share, one right and one redeemable warrant to purchase one-half of one Class A ordinary share. Each right entitles the holder to receive one-tenth of one Class A ordinary share upon the consummation of an initial business combination, and each warrant entitles the holder to purchase one-half of one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares, rights and...

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).In October 2020, Praxis submitted the IND for PRAX-114 in connection with the initiation of its randomized, placebo-controlled Phase 2/3 clinical trial for PRAX-114 in MDD, as previously discussed with the FDA at a pre-IND meeting earlier this year. At the end of the 30-day IND review period, the FDA notified the Company that the IND has been placed...

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./CALGARY, Alberta, Nov. 09, 2020 (GLOBE NEWSWIRE) — Canadian Spirit Resources Inc. (“CSRI” or the “Corporation”) (TSXV:SPI) (OTCBB:CSPUF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the “Offering“) and issued 20,000,000 units of the Corporation (“Units“), at a price of $0.05 per Unit, for aggregate gross proceeds of $1,000,000 and has also completed its previously announced shares for debt transaction whereby the Corporation settled $600,000 in outstanding debt to Elmag Investments Inc. (Investissements Elmag Inc.) (“Elmag“) by issuing 12,000,000 common shares in the capital of the Corporation (“Common Shares“) at an issuance...

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — Cornish Metals Inc. (TSX-V: CUSN) (“Cornish Metals” or the “Company”) is pleased to report that warrant holders exercised a total of 6,272,857 warrants, of which 5,222,222 warrants were part of the early warrant exercise incentive program as announced October 1, 2020 (the “Incentive Program”), for total gross proceeds of $439,100. As of November 9, 2020, following completion of the Incentive Program, 140,091,442 common shares are outstanding.Related parties (as such term is defined under applicable securities laws) of the Company were restricted in their ability to participate in the Incentive Program such that the aggregate of all Eligible Warrants to be exercised by related parties of the Company pursuant to the Incentive Program would not exceed 10% of all Eligible...

伊利诺伊州维尔梅特, Nov. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc.（Nasdaq: MNMPR，一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法）今天宣布了其2b/3期临床阶段领先候选药物Validive（可乐定HCl粘膜球菌片）最新获批的一系列专利。这些专利（包括美国专利号10,675,271）提供了涵盖“用于预防和/或治疗化学不良副作用的可乐定和/或可乐定衍生物”的权利要求。“最近获得授权的这些专利扩大了在癌症患者中使用Validive的专利保护范围，”Monopar首席科学官Andrew Mazar博士表示。“具体来说，在2035年之前，专利将为Validive预防或治疗常见化疗相关副作用（如胃肠道疾病、呼吸系统疾病、疲劳和头痛）的潜在能力提供保护。”关于Monopar Therapeutics Inc.Monopar Therapeutics是一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。Monopar处于不同研发阶段的产品包括：用于预防口咽癌症患者因化疗引起严重口腔黏膜炎的Validive®；用于治疗晚期软组织肉瘤的camsirubicin；以及用在晚期癌症和重症新冠肺炎的后期临床前抗体MNPR-101。如需获取更多信息，请访问：www.monopartx.com。前瞻性声明本新闻稿所载关于非历史事实事项的声明属于1995年《私人证券诉讼改革法案》中所述的“前瞻性声明”。“可能”、“将会”、“能够”、“将要”、“应该”、“预料”、“计划”、“预期”、“意在”、“相信”、“估计”、“预示”、“预测”、“潜在”、“继续”、“目标”和类似表达旨在标示前瞻性声明，但并非所有前瞻性声明都包含这些标示词。这些前瞻性声明的例子包括关于以下内容的声明：Monopar按计划在年底前启动Validive 2b/3期临床试验的能力；Validive预防或治疗化疗相关常见副作用（如胃肠道疾病、呼吸系统疾病、疲劳和头痛）的潜力；Validive在接受化疗的患者中预防口腔粘膜炎的潜力；Monopar“开发疗法来提高正在接受治疗的癌症患者的生活质量”这一使命的推进情况；Validive专利将加强并保护Monopar的知识产权组合。前瞻性声明涉及风险和不确定性，包括但不限于Monopar需要筹集更多资金或与合作伙伴合作以完成Validive未来的临床开发和潜在商业化（包括如果Monopar决定将目前计划的开发活动扩展到OPC以外的化疗所带来的其他不良副作用），以及与疗法的研究、开发、监管审批和商业化相关的重大一般风险和不确定性。实际结果可能与此类前瞻性声明中明示或暗示的结果存在重大差异。在Monopar向证券交易委员会提交的文件中，针对各种风险提供了更全面的描述。本新闻稿中包含的所有前瞻性声明仅适用于截至声明发布之日的情形。Monopar没有义务更新此类声明以反映声明作出后发生的事件或存在的情况。本新闻稿中包含的任何前瞻性声明仅代表Monopar截至本文日期的观点，不应被视为代表其后任何日期的意见。联系方式：Monopar...

Company remains focused on completing final steps to reposition businessCastaños, Mexico manufacturing operation received industry certifications and is now shipping railcarsSecond half delivery guidance narrowed to range between 750 and 850 railcarsCHICAGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) today reported results for the third quarter ended September 30, 2020.Business Highlights        Third quarter revenue of $25.2 million on deliveries of 163 railcarsThird quarter net loss attributed to Freight Car America. Inc. (“FCA”) of $40.3 million, or $3.03 per share, including $30.1 million, or $2.26 per share, of restructuring and impairment charges, $26.6 million of which is non-cashTotal cash, cash equivalents, restricted cash equivalents, marketable securities and restricted certificates of deposit...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTIONOR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) reports that it intends to increase the size of its previously announced non-brokered private placement of units from 2,500,000 units to 3,307,500 units (the “Private Placement”).The Private Placement will now consist of 3,307,500 units (the “Units”) at a price of $0.40 per Unit for gross proceeds of $1.323 million. Each Unit will consist of one common share in the capital of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one additional common share in the capital of the Company...

BEDFORD, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) — Legacy Housing Corporation (NASDAQ: LEGH) announces restated financial results for the second quarter ended June 30, 2020.  On November 6, 2020, Legacy Housing Corporation (the “Company”) filed an amended Quarterly Report on Form 10-Q/A restating its second quarter interim financial statements for fiscal year 2020. As a result of the restatement, investors should no longer rely upon the Company’s previously issued financial statements for the period set forth above, earnings releases for this period, and other communications relating to these financial statements.The Company identified an overstatement of costs errantly assigned to accounts payable for inventory received but not invoiced. The Company noted that these adjustments resulted in an increase to retained earnings of...